NCT03943173 is a EARLY_PHASE1 clinical trial of Chemotherapy in BRCA-Mutated Ovarian Carcinoma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT03943173?

NCT03943173 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03943173?

Interventions in NCT03943173: Chemotherapy, Olaparib, Therapeutic Conventional Surgery.

What condition does NCT03943173 study?

NCT03943173 studies BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8.

Is NCT03943173 still recruiting?

NCT03943173 is currently active, enrolled. Last updated 25 February 2026.

Last reviewed 2026-02-25 · How we verify

NCT03943173

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Active, enrolled EARLY_PHASE1 Last updated 25 February 2026

What this trial tests

EARLY_PHASE1 trial testing Chemotherapy in BRCA-Mutated Ovarian Carcinoma in 15 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 June 2019

Primary endpoint
27 June 2027

27 June 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	7 June 2019
Primary completion	27 June 2027
Estimated completion	27 June 2027
Sites	1 location across United States

Drugs / interventions tested

Chemotherapy (chemotherapy) — full drug profile →
Olaparib (olaparib) — full drug profile →
Therapeutic Conventional Surgery

Conditions studied

BRCA-Mutated Ovarian Carcinoma — all drugs for BRCA-Mutated Ovarian Carcinoma →
BRCA1 Gene Mutation — all drugs for BRCA1 Gene Mutation →
BRCA2 Gene Mutation — all drugs for BRCA2 Gene Mutation →
High Grade Fallopian Tube Serous Adenocarcinoma — all drugs for High Grade Fallopian Tube Serous Adenocarcinoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, female only, with BRCA-Mutated Ovarian Carcinoma or BRCA1 Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This early phase I trial studies how well olaparib works in treating patients with newly diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103
Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, et al · · 2022 · cited 26× · PMID 35973745 · DOI 10.1136/jitc-2022-005036
Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges.
Nikolaidi A, Fountzilas E, Fostira F, Psyrri A, et al · · 2022 · cited 21× · PMID 35957909 · DOI 10.3389/fonc.2022.820128
PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials.
Habaka M, Daly GR, Shinyanbola D, Alabdulrahman M, et al · · 2025 · cited 9× · PMID 40192976 · DOI 10.1007/s11912-025-01669-z
Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?
Quesada S, Thomas QD, Colombo PE, Fiteni F. · · 2023 · cited 7× · PMID 37509219 · DOI 10.3390/cancers15143556
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.
Mukherjee UA, Miller RE, Ledermann JA. · · 2025 · cited 2× · PMID 40529205 · DOI 10.1177/17588359251343973

Verify or expand the search:

Other trials of Chemotherapy

Trials testing the same drug.

NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting

Other recruiting trials for BRCA-Mutated Ovarian Carcinoma

Currently open trials in the same condition.

NCT04009148 — Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03943173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 25 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03943173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing